Protagonist Therapeutics shares surge as FDA approves J&J-partnered psoriasis drug
Share
Protagonist Therapeutics (NASDAQ:PTGX) announced today that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 and older weighing at least 40 kg.